Q-omics provides the consensus-scored LIPI profile across patient tissues and cancer cell-line models. LIPI expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LIPI is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, LIPI RNA expression shows 17,261 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where LIPI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIPI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIPI survival associations across molecular data types. LIPI RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIPI RNA expression–survival associations across cancer types. High LIPI expression shows unfavorable associations in KIRC, ACC, KIRP and COAD, but favorable associations in UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LIPI RNA expression.
This table summarizes LIPI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LIPI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIPI shows lower tumor expression in THCA, HNSC, BLCA and COAD and higher tumor expression in LUSC and LUAD. The THCA box plot shows higher LIPI RNA expression in normal versus tumor tissue (log2 FC = −2.902, t-test p < 0.001).
This table shows molecular features associated with LIPI in patient tissues and cancer cell lines. In patient samples, LIPI shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LIPI RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
